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Abstract
AIM: To evaluate the association between liver stiffness 
(LS) prior to the initiation of dual/triple therapy and viral 
response.
METHODS: LS was measured in all patients before 
treatment was administered. The therapeutic approach 
was based on hepatic, virological, and immunological 
evaluations and considered the fact that patients with 
severe fibrosis (F3) or compensated cirrhosis (F4) in 
Child-Pugh class A are the primary candidates for triple 
therapy. In total, 65 hepatitis C virus (HCV) patients were 
treated with Peg-interferon/ribavirin (Peg-IFN/RBV); 24 
patients were classified as genotypes 1/4 (36.92%), and 
41 patients were classified as genotypes 2/3 (63.08%) 
(dual therapy). In addition, 20 HCV treatment-experienced 
genotype 1 patients were treated with PegIFN-RBV and 
boceprevir (triple therapy). Wilcoxon rank-sum tests were 
used to compare the groups.
RESULTS: LS significantly differed between dual 
therapy and triple therapy (P  = 0.002). The mean LS 
value before dual therapy treatment was 8.61 ± 5.79 
kPa and was significantly different between patients 
achieving a sustained virologic response (SVR) 24 
weeks after therapy and those who did not (7.23 
± 5.18 kPa vs  11.72 ± 5.99 kPa, respectively, P = 
0.0003). The relative risk of non-response to therapy 
was 4.45 (95%CI: 2.32-8.55). The attributable risk 
of non-response to therapy was 49%. The mean LS 
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value before triple therapy treatment was 13.29 ± 8.57 
kPa and was significantly different between patients 
achieving and not achieving SVR24 (9.41 ± 5.05 vs  
19.11 ± 9.74, respectively; P = 0.008). The relative 
risk of non-response to therapy was 5.57% (95%CI: 
1.50-20.65). The attributable risk of non-response 
to therapy (70%) was increased compared with dual 
therapy patients. Pre-treatment stiffness > 12 kPa was 
significantly associated with non-SVR (P  < 0.025) in 
both groups.
CONCLUSION: Pre-treatment liver stiffness may be 
useful for predicting the response to treatment in patients 
treated with either dual or triple anti-HCV therapy.
Key words: Antiviral therapy; Chronic hepatitis C; Fibrosis; 
Liver stiffness; Sustained virological response
© The author(s) 2015. Published by Baishideng Publishing 
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Core tip: Transient elastography is a non-invasive, easy, 
reproducible technique that is well tolerated for staging 
non-significant fibrosis or severe fibrosis/cirrhosis. 
The assessment of liver fibrosis using transient elasto-
graphy may be useful to reduce the need for a liver 
biopsy. In this prospective study, liver stiffness values 
can also be used as a predictor of response to therapy. 
A liver stiffness value greater than 12 kPa is a negative 
predictor of response to both dual and triple therapy. 
Therefore, transient elastography could be used in 
clinical practice to improve the selection of patient 
treatment.
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INTRODUCTION
Liver fibrosis is a pathological process caused by an 
excessive accumulation of extracellular matrix that leads 
to liver cirrhosis progression. In fact, fibrosis generally 
progresses in untreated chronic viral liver diseases, 
thereby leading to excessive collagen deposition, which 
results in qualitative and quantitative changes of the 
extracellular matrix. The deposition of the fibrotic matrix 
is largely due to the recruitment of resident mesenchymal 
cells and possibly a small aliquot of circulatory cell types 
that are capable of differentiating into a myofibroblast 
phenotype[1,2]. Viral infection can cause a fibrogenic 
process that is initially concentrated around portal tracts 
and subsequently leads to the formation of portal-portal 
and portal-central septa. The fibrogenic process proceeds 
through various stages because the composition of the 
extracellular matrix changes with the advancement of 
fibrosis. The impact of the fibrosis stage on a patient’s 
response to anti-hepatitis C virus (HCV) treatment has 
been explored in several studies[3-5]. In fact, the decision 
of whether and when to start antiviral treatment for 
chronic HCV depends primarily on several variables, 
including the fibrotic stage[6]. Therefore, periodic liver 
biopsies are needed to assess the progression of fibrosis 
and select patients for antiviral treatment.
In HCV genotype 2 or 3 infected patients, liver biopsy 
is typically not performed given the high likelihood of a 
favourable therapeutic response to treatment with Peg-
interferon (INF) and ribavirin (RBV) (Peg-INF/RBV)[6]. In 
several countries, including Italy, triple therapy with Peg-
INF/RBV and either boceprevir or telaprevir currently 
serves as the standard care for HCV genotype 1 patients 
with previous treatment failure to dual therapy with 
Peg-INF/RBV. For patients who relapse on dual therapy, 
triple therapy should be initiated as soon as possible 
in the presence of advanced fibrosis (F3-F4, METAVIR 
classification)[7], whereas treatment for patients with 
moderate fibrosis can be considered on a case by case 
basis[8]. In naive patients with negative pre-treatment 
predictors of response, including genotype 1, CT-TT 
alleles of the IL28b polymorphism, and F3-F4 fibrosis 
stage, triple therapy should be introduced as first-line 
therapy.
In the last 10 years, various methods, such as 
serum markers of liver fibrosis, ultrasound[9], magnetic 
resonance imaging (MRI)[10], and transient[11] or MR-
elastography[12] have been proposed as tests. These tests 
for staging and assessing the progression/regression 
of liver fibrosis are non-invasive, easily reproducible, 
and well tolerated by patients. Several studies[13-18] 
have evaluated the outcome of IFN/RBV treatment 
through the assessment of short- and long-term longitu-
dinal assessment of liver stiffness (LS) by transient 
elastography in HCV infected patients.
New treatments for HCV infection involving triple 
therapy also require an accurate assessment of liver 
fibrosis for a correct therapeutic approach. Therefore, 
the objective of this study was to evaluate the value 
of LS prior to initiation of dual/triple therapy as a 
prognostic indicator of response to antiviral therapy in 
HCV patients.
MATERIALS AND METHODS
Eighty-five patients with chronic HCV infection (35 women 
with a mean age of 56.31 ± 11.13 years and 50 men 
with a mean age 50.55 ± 10.12 years) referred to the 
hepatology outpatient ward of the Careggi University 
Hospital, Florence, Italy between January 2012 and 
December 2012 for assessment of liver disease stage 
and eligibility for antiviral treatment conforming to the 
recommendations of the Italian Association for the Study 
of the Liver[8] were considered for potential enrolment 
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in the study. The enrolment inclusion criteria of this 
prospective study are as follows: presence of detectable 
serum HCV-RNA; eligibility for antiviral treatment; 
no antiviral or immunosuppressive therapies admini-
stered 6 mo prior to enrolment; abnormal liver enzyme 
levels; exclusion of Child-Pugh class B and C cirrhosis; 
absence of alcohol intake ≥ 40 g/d or use of hepatotoxic 
medications, hepatocellular carcinoma, acute viral 
hepatitis, co-infection with hepatitis B virus or human 
immunodeficiency virus, other hepatic disease (e.g., 
metabolic liver disease), pathologic conditions potentially 
affecting LS (i.e., cardiac failure), and physiological states 
contraindicated for this technique (e.g., pregnancy). We 
exclusively analysed patients who completed the course 
of therapy.
LS was measured in all patients before treatment. 
The therapeutic approach was based on hepatic, 
virological, and immunological evaluation and consi-
dered the fact that patients with advanced fibrosis (F3) 
or compensated cirrhosis (F4) in Child-Pugh class A are 
the primary candidates for triple therapy[8]. In total, 65 
HCV patients were administered treatment with PegIFN/
RBV (dual therapy), and 20 HCV genotype 1 treatment-
experienced patients (relapser, partial responder or 
non-responder) were administered triple therapy (Peg-
IFN/RBV/boceprevir) (triple therapy).
Patients treated with boceprevir who experienced 
an extended rapid virological response (eRVR), namely 
undetectable HCV RNA levels from week 4 through 
week 12, ended therapy at 28 wk. The other patients 
treated with boceprevir either without eRVR or with 
severe liver fibrosis in the presence of eRVR ended 
therapy at 48 wk. Patients with HCV genotypes 1/4 
treated with double therapy stopped therapy at 48 wk; 
patients with genotypes 2/3 stopped all treatment at 
24 wk[8].
Hepato-virological evaluation
The detection of HCV RNA in serum samples was 
determined by HCV-RNA Amplicor Monitor quantitative 
assay (Roche Diagnostics, Basel, Switzerland; limit of 
detection: 15 IU/mL), and HCV RNA was genotyped 
using INNO-LiPA HCV Ⅱ (Immunogenetics, Gent, 
Belgium) conforming to the technical instruction of 
manufacturers.
The degree of liver function was evaluated through 
biohumoral liver function tests and the Child-Pugh 
score[19].
IL28B genotyping was performed on DNA extracted 
from whole blood samples using a specific custom 
TaqMan Single Nucleotide Polymorphism (SNP)-
Genotyping Assay (SNP): rs12979860; Applied 
Biosystems, Foster City, CA, United States) based on 
allele-specific dual-labelled probes on a Rotor Gene 6000 
(Corbett Research, Sidney, Australia)[20].
LS was measured in all patients before treatment 
after overnight fasting using FibroScan® (Echosens, 
Paris, France) conforming to the technical instruction 
of manufacturers. We considered as representative of 
LS the median values of 10 successful measurements, 
expressed in kiloPascal (kPa). We considered reliable 
the procedures with 10 successful acquisitions and a 
success rate greater than 60% and an interquartile 
range (IQR) ≤ 30% of the median value. LS values ≥ 
12 kPa indicate advanced fibrosis[11,18].
Statistical analysis
Continuous variables were summarised by descriptive 
statistics and categorical variables were summarised 
using patient counts and percentages. All results are 
expressed as the mean ± SD. We used the Wilcoxon 
rank-sum test to compare two samples.
Relative risk (RR) is a measurement of the rela-
tionship between fibrosis and risk of non-response 
to treatment. A RR of 1.0 indicates an absence of 
association. When the RR is greater than 1.0, the 
risk of non-response to treatment is increased when 
the risk factor is present. Attributable risk (AR) is a 
measurement of the degree to which the risk of non-
response to treatment is attributed to LS > 12 kPa. RR 
is calculated as follows: risk in patients with LS > 12 
kPa/risk in patients with LS < 12 kPa. AR is calculated 
as follows: the incidence attributable to LS > 12 kPa/
proportion of incidence attributable to LS > 12 kPa.
Logistic regression analysis was used to assess the 
factors associated with sustained virological response 
(SVR), which was defined as the absence of detectable 
HCV RNA in blood samples 24 wk after discontinuing 
the therapy. Multivariate logistic regression analysis was 
used to assess which baseline variables were predictive 
of SVR. In the final model, age, gender, stiffness, and 
viraemia (and viral genotype as well as IL28B genotype 
limited to dual therapy) were considered independent 
predictors of SVR.
All statistical tests were performed at the p ≤ 0.05 
level (two-sided). Statistical analysis and graphs were 
performed using Stata 11, (College Station, TX, United 
States) and SPSS v18 (SPSS Inc., Chicago, IL, United 
States).
RESULTS
The main features of the study population at baseline 
are summarised in Table 1.
Among the 65 HCV patients treated with Peg-
IFN/RBV dual therapy, 24 patients were infected with 
genotypes 1/4 (36.92%), whereas 41 patients were 
infected with genotypes 2/3 (63.08%) (dual therapy). 
Among the 20 HCV genotype 1 treatment-experienced 
patients treated with triple therapy, 1 patient was 
infected with genotype 1a, 1 patient was infected 
with genotype 1a/1b, and 18 patients were infected 
with genotype 1b. Only LS significantly differed in 
patients on dual vs triple therapy (p = 0.002) (Table 
1). A diagnosis of liver cirrhosis (Child A) based on the 
histological and/or clinical and ultrasound data was 
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Table 2  Univariate analysis of negative prognostic factors of 
sustained virologic response in both dual and triple therapy
Table 1  Main features of the study population at baseline
made in 4 patients on dual therapy and in 8 patients 
on triple therapy.
The rates of patients achieving a sustained virologic 
response 24 wk after therapy (SVR 24) are show in 
Figure 1.
In dual therapy patients, the mean LS value before 
treatment was 8.61 ± 5.79 kPa. Mean LS values 
significantly differed between patients achieving and 
not achieving SVR 24 (7.23 ± 5.18 kPa vs 11.72 ± 5.99 
kPa, respectively, p = 0.0003). Liver stiffness > 12 kPa 
prior to the initiation of dual therapy was significantly 
associated with no SVR (p < 0.025). The relative 
risk of non-response to therapy was 4.45 (95%CI: 
2.32-8.55). The attributable risk of non-response to 
therapy was 49%.
In triple therapy patients, the mean LS value before 
treatment was 13.29 ± 8.57 kPa. Pre-treatment LS 
values significantly differed between patients achieving 
SVR 24 and those who did not (9.41 ± 5.05 vs 19.11 ± 
9.74, respectively, p = 0.008). Liver stiffness > 12 kPa 
prior to the initiation of triple therapy was significantly 
associated with no SVR (p < 0.025). The relative 
risk of non-response to therapy was 5.57% (95%CI: 
1.50-20.65). The attributable risk of non-response to 
therapy was 70%. This result was increased compared 
with dual therapy patients, which is a consequence of 
eligibility for dual or triple therapy. In fact, boceprevir 
therapy is indicated for the treatment of difficult to 
treat patients, including patients with more advanced 
fibrosis. Univariate analysis was conducted by binary 
logistic regression analysis in both groups in which the 
response to treatment was the dependent variable; 
the results indicated that LS was a good predictor of 
response (dual therapy, p = 0.03; triple therapy, p = 
0.0009) (Table 2). Multivariate regression analysis in 
dual therapy, where the independent variables included 
age, gender, stiffness, IL28B genotype, viraemia, and 
viral genotype, did not identify a predictor of treatment 
response. By contrast, in triple therapy, where the 
independent variables only included age, gender, 
stiffness, and viraemia (the IL28B polymorphism 
was always unfavourable regardless of the CT or TT 
alleles, and all patients were infected with genotype 
1), LS was the only prognostic indicator of treatment 
response (p = 0.049) (Table 3).
DISCUSSION
In this study, LS was demonstrated for the first time 
to predict a patient’s response to triple therapy. In a 
previous study[18], we observed that LS values greater 
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Baseline feature Dual therapy Triple therapy Normal range P  value
Age (yr)   51.82 ± 11.40 56.65 ± 8.24 0.16
BMI 24.65 ± 3.45 26.17 ± 3.55 18-25 0.08
Male sex 40/25 10/10
Albumin (g/dL)   4.11 ± 0.34   4.08 ± 0.49 3.5-5.0 0.95
Bilirubin (mg/dL)   0.78 ± 0.41   1.05 ± 0.21 0.3-1 0.06
Platelets (× 109/L) 190.29 ± 60.04 168.16 ± 51.08 140-440 0.18
ALT (U/L) 116.75 ± 88.69   82.88 ± 47.86 5-40 0.28
GGT (U/L)   72.16 ± 80.53   93.38 ± 77.62 10-40 0.06
C/T or T/T IL28B genotype 19.50% 100%
Liver stiffness (kPa)   8.61 ± 5.79 13.29 ± 8.57   0.002
HCV genotypes 1/4, n (%) 24 (36.92) 20 (100)
HCV genotypes 2/3, n (%) 41 (63.08) 
HCV RNA level (IU × 1000) 3459.135 ± 5541.24   4924.462 ± 6799.737 0.72
BMI: Body mass index; ALT; Alanine aminotransferase; GGT; Gamma glutamyl transpeptidase; HCV: Hepatitis C virus.
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Figure 1  Rates of patients achieving a sustained virologic response 24 wk 
after therapy (sustained virologic response 24). SVR: Sustained virologic 
response; NR: Non responders were defined by positive HCV-RNA at the end 
of at least 24 wk of treatment.
Dual therapy 
(P  value)
Triple therapy 
(P  value)
Male sex 0.33 0.39
Age ≥ 55 yr 0.40 0.47
HCV genotype 1 and 4 0.46 -
Liver stiffness > 12 kPa 0.03   0.001
C/T or T/T IL28B genotype 0.12 -
> 500000 IU HCV RNA titre 0.30 0.06
-: Omitted because of collinearity. HCV: Hepatitis C virus.
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Table 3  Multivariate analysis of negative prognostic factors 
of sustained virologic response in both dual and triple therapy
than 12 kPa were a negative prognostic indicator of 
response to Peg-IFN/RBV therapy. In this different cohort 
of patients, the attributable risk of non-response to Peg-
IFN/RBV therapy was similar but reduced compared with 
triple therapy. This difference was likely due to increased 
LS values in this latter group of patients.
The individual decision to start anti-HCV treatment 
depends largely on several factors, including liver histology, 
particularly in the difficult-to-treat HCV genotypes 1 and 
4[6]. The extent of liver fibrosis may negatively affect 
the rate of response to antiviral therapy. Thus, cirrhotic 
patients, who may derive the most benefit from viral 
eradication, have the lowest SVR rates[3-5]. On the other 
hand, SVR may be associated with regression of liver 
fibrosis in patients with significant fibrosis. In this context, 
non-invasive tools for the assessment of liver fibrosis could 
be useful to eliminate the need of liver biopsy. The study 
by Roberts et al[3] demonstrated poor SVR rates among 
patients with advanced fibrosis compared with patients 
with moderate and absent or minimal fibrosis.
Transient elastography has been suggested as a 
possible machine for the diagnosis of absent/minimal 
fibrosis or severe fibrosis/cirrhosis in chronic HCV infected 
patients[21-25]. Moreover, the technique is characterised 
by high intra- and interobserver reproducibility[22,26]. 
However, recent food intake can affect the reliability 
of stiffness values in the diagnosis of fibrosis stage in 
patients with chronic HCV infection[27,28]. In addition, 
Arena et al[28] suggest that a fasting period of 120 min 
prior to obtaining liver stiffness measurements should 
be observed. A decline in the diagnostic need for liver 
biopsies in patients with HCV-related chronic liver disease 
was recently noted because the accuracy of non-invasive 
methods, especially in predicting non-significant or 
advanced liver fibrosis, suggests that LS can also be used 
as a predictor of response to therapy.
In fact, few data are available[18] regarding the 
interpretation of LS values as direct predictors of the 
treatment response. However, several studies[3-5] have 
demonstrated an association between the fibrotic 
stage in liver biopsies and response to treatment. In 
particular, Cheng et al[4] revealed a marked step-wise 
decline in SVR rates according to fibrotic stage. This 
observation is consistent with the present study that 
demonstrates a significant relationship between LS 
and the patient’s response to treatment. The LS values 
were particularly an independent predictor of response 
in those patients administered triple therapy.
Interestingly, the difference in the response rates 
between patients with LS < 12 vs > 12 was observed 
not only in patients treated with dual therapy but also 
in those treated with triple therapy with the direct 
acting antiviral (DAA) boceprevir. These results clearly 
confirm the potential utility of LS assessment in the 
evaluation of the response to anti-HCV treatment.
In Europe, the use of first-generation DAA boceprevir 
or telaprevir-based triple therapy has generally been 
restricted to patients with more advanced fibrosis stages 
given their high cost. The SPRINT-2[29] and RESPOND-2[30] 
trials demonstrated that the addition of boceprevir to 
Peg-INF/RBV results in significantly increased SVR rates 
in difficult-to-treat patients. Moreover, the duration of 
treatment was primarily based on fibrotic stage, with 
longer treatments providing the most benefit in patients 
with F3/4[31,32].
In conclusion, our data suggest that LS > 12 kPa 
should be considered a strong prognostic indicator 
of non-response to both dual and triple therapy. This 
index may potentially serve as a useful tool for accurate 
selection of patient treatment. Further studies are 
necessary to evaluate whether patients with LS < 12 kPa 
experience different clinical outcomes compared with 
patients with LS > 12.
COMMENTS
Background
New treatments for hepatitis C virus (HCV) infection require an accurate 
assessment of liver fibrosis for a correct therapeutic approach. The main 
objective of our study was to evaluate the value of liver stiffness as a prognostic 
indicator of response to antiviral therapy in HCV patients prior to initiation of 
dual/triple therapy.
Research frontiers
First generation triple therapy is still a therapeutic option in many countries, 
where the polymerase inhibitors, inhibitors of the replication complex and 
protease inhibitors of the second generation are not yet available or still under 
way. This is mainly due to the living standards of the low and middle income 
countries. Interferon-free therapies are well tolerated and effective, but their 
high cost forces to let each patient follow cost-effective paths.
Innovations and breakthroughs
This prospective study points out that the liver stiffness values are significantly 
higher in patients who don’t respond to treatment suggesting that liver stiffness 
> 12 kPa should be considered a negative prognostic indicator.
Applications
The assessment of liver stiffness is a good option to evaluate liver fibrosis by 
means of a non invasive method. It can potentially be an useful tool for a more 
accurate selection of treatment.
Peer-review
The study is interesting and well done. In this prospective study of liver stiffness 
in 65 treatment-naive patients with HCV prior to commencing dual antiviral 
therapy, high liver stiffness values predicted a poor virological response. This 
group was compared with a group of patients who had been treated previously 
and were retreated with triple therapy. Liver stiffness was a strong predictor of 
response, especially in the latter group.
REFERENCES
1 Pinzani M. Liver fibrosis. Springer Semin Immunopathol 1999; 
21: 475-490 [PMID: 10945037]
3017 March 14, 2015|Volume 21|Issue 10|WJG|www.wjgnet.com
Dual therapy 
(P  value)
Triple therapy 
(P  value)
Male sex 0.465 0.913
Age ≥ 55 yr 0.465 0.954
HCV genotypes 1 and 4 0.622 -
Liver stiffness > 12 kPa 0.733 0.049
C/T or T/T IL28B genotype 0.622 -
> 500000 IU HCV RNA titre 0.317 0.532
-: Omitted because of collinearity. HCV: Hepatitis C virus.
 COMMENTS
Stasi C et al . Stiffness prognostic value in HCV patients
2 Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 
209-218 [PMID: 15690074 DOI: 10.1172/JCI200524282]
3 Roberts SK, Weltman MD, Crawford DH, McCaughan GW, 
Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, 
Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ. Impact of 
high-dose peginterferon alfa-2A on virological response rates in 
patients with hepatitis C genotype 1: a randomized controlled trial. 
Hepatology 2009; 50: 1045-1055 [PMID: 19676125 DOI: 10.1002/
hep.23130]
4 Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, 
Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, 
Yoshihara M, Dore GJ. Low virological response and high relapse 
rates in hepatitis C genotype 1 patients with advanced fibrosis 
despite adequate therapeutic dosing. J Hepatol 2010; 53: 616-623 
[PMID: 20619475 DOI: 10.1016/j.jhep.2010.04.024]
5 El Raziky M, Attia D, El Akel W, Shaker O, Khatab H, Abdo 
S, Elsharkawy A, Esmat G. Hepatic fibrosis and serum alpha-
fetoprotein (AFP) as predictors of response to HCV treatment and 
factors associated with serum AFP normalisation after treatment. 
Arab J Gastroenterol 2013; 14: 94-98 [PMID: 24206736 DOI: 
10.1016/j.ajg.2013.08.005]
6 European Association for the Study of the Liver. EASL Clinical 
Practice Guidelines: management of hepatitis C virus infection. 
J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/
j.jhep.2011.02.023]
7 Bedossa P, Poynard T. An algorithm for the grading of activity 
in chronic hepatitis C. The METAVIR Cooperative Study Group. 
Hepatology 1996; 24: 289-293 [PMID: 8690394]
8 Associazione Italiana Per Lo Studio Del Fegato. Parere dell’
Associazione Italiana per lo Studio del Fegato (AISF) sull’uso 
della triplice-terapia (Peg-IFN Ribavirina inibitore delle proteasi 
di prima generazione) per il trattamento dei pazienti con epatite 
cronica da HCV genotipo 1. Available from: URL: http://www.
webaisf.org/media/16360/position_paper_definitivo.pdf
9 Nishiura T, Watanabe H, Ito M, Matsuoka Y, Yano K, Daikoku M, 
Yatsuhashi H, Dohmen K, Ishibashi H. Ultrasound evaluation of 
the fibrosis stage in chronic liver disease by the simultaneous use 
of low and high frequency probes. Br J Radiol 2005; 78: 189-197 
[PMID: 15730982]
10 Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K, Iio 
E, Miyaki T, Joh T. Noninvasive evaluation of hepatic fibrosis in 
hepatitis C virus-infected patients using ethoxybenzyl-magnetic 
resonance imaging. J Gastroenterol Hepatol 2013; 28: 1032-1039 
[PMID: 23432660 DOI: 10.1111/jgh.12181]
11 Stasi C, Arena U, Vizzutti F, Zignego AL, Monti M, Laffi G, Corti 
G, Pinzani M. Transient elastography for the assessment of liver 
fibrosis in patients with chronic viral hepatitis: the missing tool? 
Dig Liver Dis 2009; 41: 863-866 [PMID: 19482565 DOI: 10.1016/
j.dld.2009.04.002]
12 Ichikawa S, Motosugi U, Ichikawa T, Sano K, Morisaka H, 
Enomoto N, Matsuda M, Fujii H, Araki T. Magnetic resonance 
elastography for staging liver fibrosis in chronic hepatitis C. Magn 
Reson Med Sci 2012; 11: 291-297 [PMID: 23269016]
13 Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. 
The longitudinal quantitative assessment by transient elastography 
of chronic hepatitis C patients treated with pegylated interferon 
alpha-2b and ribavirin. Antiviral Res 2009; 83: 127-134 [PMID: 
19443053 DOI: 10.1016/j.antiviral.2009.04.002]
14 Arima Y, Kawabe N, Hashimoto S, Harata M, Nitta Y, Murao 
M, Nakano T, Shimazaki H, Kobayashi K, Ichino N, Osakabe K, 
Nishikawa T, Okumura A, Ishikawa T, Yoshioka K. Reduction of 
liver stiffness by interferon treatment in the patients with chronic 
hepatitis C. Hepatol Res 2010; 40: 383-392 [PMID: 20236358]
15 Macías J, del Valle J, Rivero A, Mira JA, Camacho A, Merchante 
N, Pérez-Camacho I, Neukam K, Rivero-Juárez A, Mata R, Torre-
Cisneros J, Pineda JA. Changes in liver stiffness in patients with 
chronic hepatitis C with and without HIV co-infection treated with 
pegylated interferon plus ribavirin. J Antimicrob Chemother 2010; 
65: 2204-2211 [PMID: 20656678 DOI: 10.1093/jac/dkq272]
16 Wang JH, Changchien CS, Hung CH, Tung WC, Kee KM, 
Chen CH, Hu TH, Lee CM, Lu SN. Liver stiffness decrease 
after effective antiviral therapy in patients with chronic hepatitis 
C: Longitudinal study using FibroScan. J Gastroenterol 
Hepatol 2010; 25: 964-969 [PMID: 20546451 DOI: 10.1111/
j.1440-1746.2009.06194.x]
17 Martinez SM, Foucher J, Combis JM, Métivier S, Brunetto 
M, Capron D, Bourlière M, Bronowicki JP, Dao T, Maynard-
Muet M, Lucidarme D, Merrouche W, Forns X, de Lédinghen V. 
Longitudinal liver stiffness assessment in patients with chronic 
hepatitis C undergoing antiviral therapy. PLoS One 2012; 7: 
e47715 [PMID: 23082200 DOI: 10.1371/journal.pone.0047715]
18 Stasi C, Arena U, Zignego AL, Corti G, Monti M, Triboli E, 
Pellegrini E, Renzo S, Leoncini L, Marra F, Laffi G, Milani S, 
Pinzani M. Longitudinal assessment of liver stiffness in patients 
undergoing antiviral treatment for hepatitis C. Dig Liver Dis 2013; 
45: 840-843 [PMID: 23660078 DOI: 10.1016/j.dld.2013.03.023]
19 Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams 
R. Transection of the oesophagus for bleeding oesophageal varices. 
Br J Surg 1973; 60: 646-649 [PMID: 4541913]
20 Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, 
Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. 
Value of IL28B genotyping in patients with HCV-related mixed 
cryoglobulinemia: results of a large, prospective study. J Viral Hepat 
2013; 20: e107-e114 [PMID: 23490377 DOI: 10.1111/jvh.12017]
21 Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, 
Adhoute X, Bertet J, Couzigou P, de Lédinghen V. Diagnosis of 
cirrhosis by transient elastography (FibroScan): a prospective 
study. Gut 2006; 55: 403-408 [PMID: 16020491]
22 Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, 
Ronchi G, Colombo M. Reproducibility of transient elastography 
in the evaluation of liver fibrosis in patients with chronic liver 
disease. Gut 2007; 56: 968-973 [PMID: 17255218 DOI: 10.1136/
gut.2006.111302]
23 Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto 
P, Bonino F, Brunetto MR. Transient elastography: a new 
surrogate marker of liver fibrosis influenced by major changes of 
transaminases. J Viral Hepat 2007; 14: 360-369 [PMID: 17439526 
DOI: 10.1111/j.1365-2893.2006.00811.x]
24 Arena U, Vizzutti F, Abraldes JG, Corti G, Stasi C, Moscarella S, 
Milani S, Lorefice E, Petrarca A, Romanelli RG, Laffi G, Bosch 
J, Marra F, Pinzani M. Reliability of transient elastography for the 
diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57: 
1288-1293 [PMID: 18448567 DOI: 10.1136/gut.2008.149708]
25 Sagir A , Erhardt A, Schmitt M, Häussinger D. Transient 
elastography is unreliable for detection of cirrhosis in patients 
with acute liver damage. Hepatology 2008; 47: 592-595 [PMID: 
18098325]
26 Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista 
A, Fruhwirth R, Marcellini M, Pinzani M. Accuracy and 
reproducibility of transient elastography for the diagnosis of 
fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 
48: 442-448 [PMID: 18563842 DOI: 10.1002/hep.22376]
27 Mederacke I, Wursthorn K, Kirschner J, Rifai K, Manns MP, 
Wedemeyer H, Bahr MJ. Food intake increases liver stiffness 
in patients with chronic or resolved hepatitis C virus infection. 
Liver Int 2009; 29: 1500-1506 [PMID: 19732330 DOI: 10.1111/
j.1478-3231.2009.02100.x]
28 Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, 
Bedogni G, Piazzolla V, Badea R, Laffi G, Marra F, Mangia A, 
Pinzani M. Liver stiffness is influenced by a standardized meal in 
patients with chronic hepatitis C virus at different stages of fibrotic 
evolution. Hepatology 2013; 58: 65-72 [PMID: 23447459 DOI: 
10.1002/hep.26343]
29 Poordad F , McCone J, Bacon BR, Bruno S, Manns MP, 
Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai 
N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki 
JP. Boceprevir for untreated chronic HCV genotype 1 infection. 
N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 
10.1056/NEJMoa1010494]
30 Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem 
3018 March 14, 2015|Volume 21|Issue 10|WJG|www.wjgnet.com
Stasi C et al . Stiffness prognostic value in HCV patients
S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs 
M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously 
treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 
1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
31 Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman 
Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht 
JK, Brass CA, Thompson S, Burroughs MH. Efficacy and safety 
of boceprevir plus peginterferon-ribavirin in patients with HCV 
G1 infection and advanced fibrosis/cirrhosis. J Hepatol 2013; 58: 
479-487 [PMID: 23183529 DOI: 10.1016/j.jhep.2012.11.020]
32 Tural C, Planas R. [Clinical use of telaprevir: stopping rules, 
predicting response, treatment length, and management of adverse 
effects]. Enferm Infecc Microbiol Clin 2013; 31 Suppl 3: 19-25 
[PMID: 24063899 DOI: 10.1016/S0213-005X(13)70120-4]
P- Reviewer: Badea R, Cosgrove D, Oramasionwu CU 
S- Editor: Ma YJ    L- Editor: A    E- Editor: Liu XM
3019 March 14, 2015|Volume 21|Issue 10|WJG|www.wjgnet.com
Stasi C et al . Stiffness prognostic value in HCV patients
                                      © 2015 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9   7 7 1 0  07   9 3 2 0 45
1  0
